

### Journalbeiträge

1. Ecke I, Petry F, Rosenberger A, Tauber S, Mönkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen Steven A, Uhmann A, Nitzki F, Wojnowski L, Schulz-Schaeffer W, Witt O, Hahn H (2009) Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. *CANCER RES*, 69(3): 887-95.
2. Georges SA, Chau BN, Braun CJ, Zhang X, Dobbstein M (2009) Cell cycle arrest or apoptosis by p53: are microRNAs-192/215 and -34 making the decision? *Cell Cycle (Internet-Ausgabe)*, 8(5): 680-1.
3. Johnsen Steven A, Güngör C, Prenzel T, Riethdorf S, Riethdorf L, Taniguchi-Ishigaki N, Rau T, Tursun B, Furlow JD, Sauter G, Scheffner M, Pantel K, Gannon F, Bach I (2009) Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. *CANCER RES*, 69(1): 128-36.
4. Lizé M, Pilarski S, Dobbstein M (2009) E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. *Cell Death Differ (Internet-Ausgabe)*, Dec 4: 1-7.
5. Morawska-Onyszczuk M, Bie kowska-Szewczyk K, Dobbstein M (2009) Self-association of adenovirus type 5 E1B-55 kDa as well as p53 is essential for their mutual interaction. *Oncogene (Internet-Ausgabe)*, dec. 21: 461.
6. Pirngruber J, Shchebet A, Johnsen S (2009) Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. *Cell Cycle (Internet-Ausgabe)*, 8(22): -.
7. Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD, Eick D, Aylon Y, Oren M, Johnsen SA (2009) CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. *EMBO Rep (Internet-Ausgabe)*, 10(8): 894-900.
8. Scheel AHJ, Beyer U, Agami R, Dobbstein M (2009) Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression. *Cell Cycle (Internet-Ausgabe)*, 8(9): 1426-32.
9. Talos F, Wolff S, Beyer U, Dobbstein M, Moll UM (2009) Brdm2-an aberrant hypomorphic p63 allele. *Cell Death Differ (Internet-Ausgabe)*, 17(1): 184-6.
10. Wolff S, Talos F, Palacios G, Beyer U, Dobbstein M, Moll UM (2009) The alpha/beta carboxy-terminal domains of p63 are required for skin and limb development. New insights from the Brdm2 mouse which is not a complete p63 knockout but expresses p63 gamma-like proteins. *CELL DEATH DIFFER*, 16(8): 1108-17.

### Medizinische Dissertationen

1. Braun C, Dr. med., MikroRNA-Moleküle als Effektoren des Tumorsuppressors p53. Dissertation Universität Göttingen 2009.